Increase in percent free prostate-specific antigen in men with chronic kidney disease.

Increase in percent free prostate-specific antigen in men with chronic kidney disease.

BACKGROUND: Prostate-specific antigen (PSA) occurs in different molecular forms in serum: free PSA (fPSA) and complexed PSA (cPSA), the sum of which corresponds to total PSA (tPSA). In addition to tPSA, percent fPSA is widely used in the detection of prostate cancer. Free PSA, approximately 28 kDa,...

Bibliográfalaš dieđut
Váldodahkkit:	Bruun, L, Savage, C, Cronin, A, Hugosson, J, Lilja, H, Christensson, A
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2009

Geahča maid

Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
Dahkki: Bruun, L, et al.
Almmustuhtton: (2003)

Editorial comment. Association between glomerular filtration rate, free, total, and percent free prostate-specific antigen.
Dahkki: Christensson, A, et al.
Almmustuhtton: (2010)

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
Dahkki: Christensson, A, et al.
Almmustuhtton: (2011)

Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
Dahkki: Bruun, L, et al.
Almmustuhtton: (2005)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2010)

Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.
Dahkki: Bruun, L, et al.
Almmustuhtton: (2004)

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
Dahkki: Becker, C, et al.
Almmustuhtton: (2000)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
Dahkki: Savage, C, et al.
Almmustuhtton: (2010)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
Dahkki: Aus, G, et al.
Almmustuhtton: (2004)

Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml−1
Dahkki: Rui Chen, et al.
Almmustuhtton: (2015-01-01)

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
Dahkki: Zackrisson, B, et al.
Almmustuhtton: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
Dahkki: Becker, C, et al.
Almmustuhtton: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
Dahkki: Becker, C, et al.
Almmustuhtton: (2003)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2010)

The Impact of the Percent of Residual Prostate-Specific Antigen on Metastasis-Free Survival in Patients with Persistent Prostate-Specific Antigen after Radical Prostatectomy
Dahkki: Dan Bee Lee, et al.
Almmustuhtton: (2023-01-01)

Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection.
Dahkki: Zackrisson, B, et al.
Almmustuhtton: (2003)

Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
Dahkki: Aus, G, et al.
Almmustuhtton: (2003)

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
Dahkki: Hugosson, J, et al.
Almmustuhtton: (2003)

[Isoforms of free prostate-specific antigen]
Dahkki: Haese, A, et al.
Almmustuhtton: (2004)

Isoforms of free prostate-specific antigen
Dahkki: Haese, A, et al.
Almmustuhtton: (2004)

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2009)

Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
Dahkki: Nurmikko, P, et al.
Almmustuhtton: (2001)

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml.
Dahkki: Rui Chen, et al.
Almmustuhtton: (2015-01-01)

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
Dahkki: Hugosson, J, et al.
Almmustuhtton: (2004)

Biology of prostate-specific antigen
Dahkki: Lilja, H
Almmustuhtton: (2003)

Biology of prostate-specific antigen.
Dahkki: Lilja, H
Almmustuhtton: (2003)

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
Dahkki: Hugosson, J, et al.
Almmustuhtton: (2003)

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.
Dahkki: Aus, G, et al.
Almmustuhtton: (2005)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2009)

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.
Dahkki: Ulmert, D, et al.
Almmustuhtton: (2006)

Evaluation of a new immunoassay for cystatin C, based on a double monoclonal principle, in men with normal and impaired renal function.
Dahkki: Ristiniemi, N, et al.
Almmustuhtton: (2012)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2010)

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
Dahkki: Evans-Axelsson, S, et al.
Almmustuhtton: (2012)

Ratios of Free to Total Prostate-Specific Antigen and Total Prostate Specific Antigen to Protein Concentrations in Saliva and Serum of Healthy Men
Dahkki: Fahimeh Kamalian, et al.
Almmustuhtton: (2007-02-01)

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
Dahkki: Klein, R, et al.
Almmustuhtton: (2012)

Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees.
Dahkki: Bergdahl, A, et al.
Almmustuhtton: (2009)

The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men
Dahkki: Jeremy YC Teoh, et al.
Almmustuhtton: (2017-01-01)

The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
Dahkki: Zackrisson, B, et al.
Almmustuhtton: (2004)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
Dahkki: Lilja, H, et al.
Almmustuhtton: (2008)

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level.
Dahkki: Törnblom, M, et al.
Almmustuhtton: (2001)